INTRODUCTION

Alport Syndrome (AS) is a clinically and genetically heterogeneous, progressive nephropathy caused by mutations in \( \text{COL4A3} \), \( \text{COL4A4} \), and \( \text{COL4A5} \) genes, which encode type IV collagen (Gubler, 2008; Hudson, Tryggvason, Sundaramoorthy, & Neilson, 2003). The \( \alpha3 \), \( \alpha4 \) and \( \alpha5 \) chains heterotrimer of type IV collagen is essential for the structure and function.

Abstract

Background: Alport syndrome (AS) is an inherited progressive renal disease caused by mutations in \( \text{COL4A3} \), \( \text{COL4A4} \), and \( \text{COL4A5} \) genes. The large sizes of these genes and the absence of mutation hot spots have complicated mutational analysis by routine PCR-based approaches. In recent years, the development of next-generation sequencing (NGS) has made possible the time- and cost-effective and accurate analysis of the three genes in a single step.

Methods: Here, we analyze \( \text{COL4A3} \), \( \text{COL4A4} \), and \( \text{COL4A5} \) simultaneously in 29 AS patients using NGS. Candidate mutations were validated by classic Sanger sequencing and Real-time PCR.

Results: Twenty two new mutations and 10 known mutations were detected. Of those novel mutations, 18, 3, and 1 mutations were detected in \( \text{COL4A5} \), \( \text{COL4A4} \), and \( \text{COL4A3} \), respectively. Twenty six patients showed \( X \)-linked inheritance, one showed autosomal recessive inheritance and two showed digenic inheritance (DI).

Conclusion: A comparison of the clinical manifestations caused by different types of mutations in \( \text{COL4A5} \) suggested that large fragment mutations are relatively more severe than the other missense mutations and AS by some mutations may show inter- and intra-familial phenotypic variability. It is important to consider these transmission patterns in the clinical evaluation according to the results of genetic testing, especially for DI. Twenty two new mutations can expand the genotypic spectrum of AS.

KEYWORDS

Alport syndrome, digenic inheritance, next-generation sequencing, novel mutations
of the basement membrane in the glomeruli of the kidney, cochlea, and eye. X-linked dominant inheritance pattern (XLAS, OMIM no. 301050) due to mutations in COL4A5, which is located in the Xq22 region (Pirson, 1999), accounts for approximately 65% of patients with Alport syndrome; autosomal dominant (ADAS, OMIM no.104200) due to COL4A3 or COL4A4 heterozygous mutations located in 2q36.3 are related to approximately 20% of patients, and the remaining 15% are autosomal recessive (ARAS, OMIM no. 203780) due to biallelic mutations in COL4A3 or COL4A4 (Kashtan, 1993). In addition, with the development of next-generation sequencing (NGS) technology, the existence of digenic inheritance (DI) has recently been demonstrated in AS with two mutations in the alpha 3-4-5 collagen IV genes (Fallerini et al., 2017; Mencarelli et al., 2015).

In AS, a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities (sensorineural deafness and ocular changes) to isolated hematuria with a typically benign course is observed (Wei et al., 2006). The rate of progression to end-stage renal disease (ESRD) and the presence or absence of sensorineural deafness and ocular changes depends on the mutation they carry (Bekheirnia et al., 2010; Jais et al., 2003). All males with XLAS develop proteinuria and, eventually, progressive renal insufficiency, which leads to ESRD (Barker et al., 1990; Kashtan, 1993). Overall, an estimated 60% reach ESRD by age 30, and 90% by age 40 (Jais et al., 2000). However, the female patients have more variable symptoms, from isolated hematuria to ESRD. Approximately, 12% of females with XLAS develop ESRD before age 40, increasing to 30% by age 60 and 40% by age 80 (Gross, Netzer, Lambrecht, Seibold, & Weber, 2002; Jais et al., 2003). Most individuals with ARAS develop significant proteinuria in late childhood or early adolescence and ESRD before age 30 (Kashtan, 2007; Mochizuki et al., 1994). Progression to ESRD occurs at a slower pace in individuals with ADAS (frequently delayed until later adulthood) than in those with XLAS or ARAS (Kamiyoshi et al., 2016).

AS shows high inter- and intrafamilial phenotypic variability, as well as high allelic heterogeneity (Lemmink, Schroder, Monnens, & Smeets, 1997). Approximately, 1,400 different mutations have been collectively reported in the three collagen IV genes (Human Gene Mutation Database, HGMD: http://hgmd.cf.ac.uk, 2018.1). There are 52, 48, and 51 coding exons for COL4A3, COL4A4, and COL4A5, respectively. The large size of these genes and the absence of mutational hot spots have hindered comprehensive genetic screenings in large patient series. In recent years, the development of NGS has made possible the time- and cost-effective and accurate analysis of the three genes in a single step (Artuso et al., 2012; Stokman et al., 2016).

In this study, we applied NGS to analyze COL4A3, COL4A4, and COL4A5 simultaneously in 29 patients with clear clinical evidences but no molecular diagnosis.

## MATERIALS AND METHODS

### 2.1 Ethical compliance

The study and procedures were approved by the Research Ethics Committee of Zhengzhou University. All subjects gave their informed signed consents.

### 2.2 Patients and families

According to standard criteria, twenty nine patients diagnosed with AS, were elected from unrelated Chinese families from 75 patients from 2016 to 2017. For each subject, clinical data were collected regarding kidney function (haematuria, proteinuria, chronic renal failure or ESRD) and extra-renal manifestations (high tone sensorineural hearing loss and ocular lesions). Detailed data on microscopic examination of kidney biopsies were also collected when available. A brief clinical summary of the patients is shown in (Table 1). A sample of peripheral blood in EDTA tubes was collected from probands and all available family members.

### 2.3 Inclusion criteria

All patients diagnosed with AS in this study satisfied one of the following criteria: (a) hematuria and proteinuria or ESRD with renal pathology showing thickening and thinning with lamellation in the glomerular basement membrane (basket weave change [BWC]) and mutations in COL4A5 or compound heterozygous mutations in COL4A3 and/or COL4A4; (b) hematuria and proteinuria with renal pathology showing thin basement membrane (TBM) and a family history of ESRD, with mutations in COL4A5 or compound heterozygous mutations in COL4A3 and/or COL4A4.

### 2.4 Samples and DNA extraction

Genomic DNA was extracted from EDTA peripheral blood samples using Lab-Aid® 824 DNA Extraction Kit according to the manufacturer’s protocol (ZEESAN, Xiamen, China).

### 2.5 Custom panel design

In order to perform mutational screening of patients presenting with a clinical suspicion of AS, we created a custom panel for COL4A3, COL4A4, and COL4A5 genes using the “Ion AmpliSeq™ designer” software (www.ampliseq.com). We targeted the coding regions and all the flanking introns up to 50 bps. The 3’ and 5’ UTR were not included in the panel design. The total coverage of the panel for the three genes was 99.87%, with 9 bps being left out from COL4A4, 87 bps being left out from COL4A3 and 94 bps from COL4A5 and it consisted of two different PCR primers pools containing 98...
TABLE 1 Clinical and pathological features of all the patients

| IID | Sex | Age | URBC (10⁴/ml) | U-P/Cr (g/g) | eGFR (ml/min/1.73 m²) | Hearing Loss | EE | Renal biopsy |
|-----|-----|-----|-------------|-------------|----------------------|-------------|----|--------------|
|     |     |     |             |             |                      |             |    |              |
| 1   | M   | 21  | 150         | 0.45        | 35                   | Normal      | n.a.| BWC Nor/A    |
| 2   | M   | 3   | 80          | 1.23        | 67.8                 | Normal      | n.a.| BWC M/A      |
| 3   | F   | 28  | 650         | 0.39        | 80.8                 | Mild        | Normal| BWC A/A      |
| 4   | M   | 31  | 320         | 0.54        | 54                   | Mild        | Normal| BWC M/A      |
| 5   | M   | 8   | 258         | 1.59        | 61.2                 | Normal      | Normal| BWC A/A      |
| 6   | M   | 3   | 196         | 1.26        | 80.9                 | Normal      | n.a.| BWC A/A      |
| 7   | F   | 16  | 78          | 0.71        | 112.5                | Normal      | Normal| BWC M/A      |
| 8   | M   | 6   | 125         | 0.35        | 36                   | Normal      | Normal| BWC M/M      |
| 9   | F   | 5   | 101         | 1.48        | 68                   | Normal      | Normal| TBM M/M      |
| 10  | F   | 2   | 203         | 0.97        | 85.6                 | Normal      | n.a.| TBM M/M      |
| 11  | F   | 7   | 246         | 0.76        | 71.7                 | Normal      | Normal| ND Nor/Nor   |
| 12  | F   | 11  | 691         | 1.27        | 65.4                 | Normal      | Normal| BWC M/A      |
| 13  | M   | 30  | 450         | 1.01        | 20.8                 | Mild        | Normal| BWC M/A      |
| 14  | M   | 10  | 69          | 1.35        | 81.3                 | Normal      | Normal| BWC M/A      |
| 15  | F   | 33  | 109         | 1.46        | 76.4                 | Normal      | Normal| TBM M/ M     |
| 16  | M   | 30  | 185         | 0.89        | 79.9                 | Mild        | Normal| BWC M/A      |
| 17  | M   | 8   | 112         | 1.59        | 48.6                 | Normal      | Normal| BWC Nor/A    |
| 18  | F   | 9   | 219         | 0.91        | 84.9                 | Normal      | Normal| BWC Nor/M    |
| 19  | M   | 1   | 318         | 1.06        | 88.3                 | Normal      | n.a.| BWC A/A      |
| 20  | M   | 12  | 69          | 0.99        | 89.2                 | Normal      | Normal| BWC A/A      |
| 21  | F   | 5   | 205         | 0.41        | 117.3                | Normal      | Normal| TBM Nor/M    |
| 22  | M   | 15  | 153         | 0.54        | 123.6                | Mild        | Normal| BWC M/A      |
| 23  | F   | 24  | 94          | 1.28        | 92.3                 | Normal      | Normal| BWC M/ M     |
| 24  | M   | 24  | 177         | 0.89        | 76.5                 | Mild        | Normal| BWC M/A      |
| 25  | M   | 3   | 82          | 1.98        | 41                   | Normal      | n.a.| BWC Nor/M    |
| 26  | F   | 4   | 125         | 1.87        | 51.6                 | Normal      | n.a.| BWC M/ M     |
| 27  | F   | 37  | 165         | 1.12        | 78.6                 | Normal      | Normal| BWC Nor/Nor  |
| 28  | F   | 37  | 286         | 1.05        | 92.9                 | Normal      | Normal| BWC M/ M     |
| 29  | M   | 5   | 376         | 0.32        | 76.4                 | Normal      | n.a.| TBM M/ M     |

Abbreviations: A, absence; BWC, basket-weave change; EE, eye examination; eGFR, estimated glomerular filtration rate ml/min/1.73 m²; EM, electron microscope; FH, family history; IID, individual ID; Pro, proteinuria (g/24 hr); M, mosaic; N, negative; n.a., not available; Nor, normal; P, positive; TBM, thin basement membrane; U-P/Cr, urinary protein-to-creatinine ratio; URBC, urine red blood cell (10⁴/ml).

and 96 amplicons respectively, with amplicon sizes ranged from 189 to 238 bps. All missing regions were screened in all samples with Sanger sequencing.

2.6 Ion torrent PGM sequencing

The library preparation was performed by amplifying 10 ng of genomic DNA, using the Ion AmpliSeq™ Library Kit 2.0 (Life Technologies). This kit allowed obtaining a barcoded library of the 194 amplicons, corresponding to the 151 exons of COL4A3/COL4A4/COL4A5 genes compatible with the Ion PGM platform, according to the Life Technologies protocol. Libraries were purified using Agencourt® AMPure® XP system and quantified using the Qubit® dsDNA HS Assay Kit reagent (Invitrogen Corporation, Life Technologies, Carlsbad, CA), pooled at an equimolar ratio, annealed to carrier spheres (Ion Sphere™ Particles, Life Technologies) and clonally amplified by emulsion PCR (emPCR) using the Ion OneTouch™ 2 system (Ion PGM™ Template Hi-Q™ view OT2 200 kit, Life Technologies). The spheres, carrying single-stranded DNA templates, were loaded to 316™v2 chip and sequenced on the Ion Torrent PGM, using the Ion PGM™ Hi-Q™ view Sequencing 200 kit v2, according to the protocol of Life Technologies. Postrun analysis was conducted using the latest version (v5.0.4) of the data analysis software Torrent Suite™ (Life Technologies). Coverage
| Sample IID | Gene Symbol | Zygosity | Function     | cHGVS       | pHGVS       | Clinical significance | Fr.1  | Fr.2  | Fr.3  | Comment                              |
|------------|-------------|-----------|--------------|-------------|-------------|-----------------------|-------|-------|-------|--------------------------------------|
| 1          | COL4A5      | hem       | Missense     | c.3799G > A | p.(Gly1267Ser) | VUS                   | –     | –     | –     | Novel                               |
| 2          | COL4A5      | hem       | Missense     | c.1717G > A | p.(Gly573Ser)  | VUS                   | –     | –     | –     | Novel                               |
| 3          | COL4A5      | het       | Missense     | c.4550G > A | p.(Arg1517His) | LP                    | –     | 0.00002 | –     | Known (Cheong, Park, Ha, & Choi, 2000) |
|            |             |           | Nonsense     | c.4705C > T | p.(Arg1569Ter) | P                     | –     | –     | –     | Known (Zhou et al., 1993)           |
| 4          | COL4A5      | hem       | Missense     | c.2210G > A | p.(Gly737Ser)  | VUS                   | –     | –     | –     | Novel                               |
| 5          | COL4A5      | hem       | Deletion     | del ex37–46 | –            | P                     | –     | –     | –     | Novel                               |
| 6          | COL4A5      | hem       | Deletion     | del ex35–36 | –            | P                     | –     | –     | –     | Novel                               |
| 7          | COL4A5      | het       | Frameshift   | c.3306_3313del | p.(Pro1103Alafs*31) | P              | –     | –     | –     | Novel                               |
| 8          | COL4A5      | hem       | Missense     | c.2723G > A | p.(Gly908Glu)  | VUS                   | –     | –     | –     | Novel                               |
| 9          | COL4A5      | het       | Frameshift   | c.1151delIT | p.(Pro385Leufs*89) | P              | –     | –     | –     | Novel                               |
| 10         | COL4A5      | het       | Missense     | c.4175T > C | p.(Leu1392Pro)  | VUS                   | –     | 0.00003 | 0.000529 | Novel                               |
| 11         | COL4A5      | het       | Missense     | c.1754G > C | p.(Gly585Ala)  | VUS                   | –     | –     | –     | Novel                               |
| 12         | COL4A5      | het       | Missense     | c.1807G > A | p.(Gly603Ser)  | VUS                   | –     | –     | –     | Novel                               |
| 13         | COL4A5      | hem       | Missense     | c.2597G > A | p.(Gly866Glu)  | LP                    | –     | –     | –     | Known (Renieri et al., 1996)        |
| 14         | COL4A5      | het       | Frameshift   | c.3706delC  | p.(Pro1237Qlnfs*68) | P              | –     | –     | –     | Novel                               |
| 15         | COL4A5      | het       | Missense     | c.973G > A  | p.(Gly325Arg)  | LP                    | –     | –     | –     | Known (Knebelmann et al., 1992)     |
| 16         | COL4A5      | hem       | Missense     | c.4462G > C | p.(Gly1487Ala) | LP                    | –     | –     | –     | Known (Plant, Green, Vetrie, & Flinter, 1999) |
| 17         | COL4A5      | hem       | Missense     | c.1957G > A | p.(Gly653Ser)  | LP                    | –     | –     | –     | Known (Boye et al., 1995)           |
| 18         | COL4A5      | het       | Missense     | c.2215C > G | p.(Pro739Ala)  | VUS                   | 0.0028 | 0.0034 | 0.01416 | Known (F. Wang et al., 2012)        |
| 19         | COL4A5      | hem       | Missense     | c.3535G > A | p.(Gly1179Arg) | LP                    | –     | –     | 0      | Known (Nagel, Nagorka, & Gross, 2005) |
| 20         | COL4A5      | hem       | Missense     | c.2632G > A | p.(Gly878Arg)  | VUS                   | –     | –     | –     | Novel                               |
| 21         | COL4A5      | het       | Missense     | c.688G > A  | p.(Gly230Ser)  | VUS                   | –     | –     | –     | Novel                               |
| 22         | COL4A5      | hem       | Missense     | c.1616G > T | p.(Gly553Val)  | VUS                   | –     | –     | –     | Novel                               |
| 23         | COL4A5      | het       | Missense     | c.2351G > T | p.(Gly784Val)  | VUS                   | –     | –     | –     | Novel                               |
| 24         | COL4A5      | hem       | Splicing     | c.277-1G > T | –            | P                     | –     | –     | 0      | Known (Plant et al., 1999)          |
| 25         | COL4A5      | hem       | Splicing     | c.439-1G > A | –            | P                     | –     | –     | –     | Known (Hanson, Storey, Pagan, & Flinter, 2011) |

(Continues)
assessment was performed using the “coverage Analysis” plug-in (v5.0.4) that gives information about the amplicons read coverage and variants were called using the “variant Caller” plug-in (5.0.4).

2.7 | Real-time PCR

To identify the fragment deletion, real-time PCR was performed using a SYBR Green PCR kit (TAKARA) in a Real-Time PCR Detection System (BIO-RAD IQ2). Melting curve analysis was performed to ensure the amplification of a single product. The data were analyzed according to the comparative Ct method. Relative quantification (RQ) = 2^\Delta\Delta Ct.

3 | RESULTS

3.1 | Identification of candidate mutations in COL4A3, COL4A4, and COL4A5

In the 29 patients, we identified 20 missense mutations, two nonsense mutations, three frameshift mutations, two deletion mutations, and five splicing site mutations. Among these, 10 were known mutations that had been reported previously and 22 were novel ones (Table 2); 50% (16/32) were new amino acid substitutions of glycine. These candidate mutations were validated by Sanger sequencing. The predicted clinical significances of these mutations are listed in Table 2 and the criteria of clinical significance are based on American College of Medical Genetics (Richards et al., 2015).

There are two patients with AS carrying two mutations in two distinct collagen IV genes. In AS patient IID27, the two mutations in COL4A5 and COL4A4 were inherited independently, likely indicating an in trans configuration. There is a splicing site mutation c.1339 + 3A>T in COL4A5, inherited from her mother and a missense mutation c.4421C > T (p. (Thr1474Met)) inherited from her father (Figure 1a). In AS patient IID29, in addition to a glycine substitution (p. (Gly1119Asp)) in COL4A3 in the heterozygous state, there was another heterozygous nonsense mutation c.5026C > T in COL4A4 genes. The two mutations were in cis configuration, inherited together on the same chromosome from her father (Figure 1b).

3.2 | Identification of fragment deletions in COL4A5

There are two patients carrying fragment deletion in COL4A5, which were validated by qPCR (Figure 2). A hemizygous deletion of exon 37–46 was identified in IID5 (Figure 2a), who had hematuria and proteinuria at age 8, and the deletion was inherited from his mother, who had hematuria. In IID6, who had intermittent hematuria and proteinuria since age 2, there was a hemizygous deletion of exon35-36 (Figure 2b) and the deletion was inherited from his mother, who had hematuria and proteinuria.
DISCUSSION

Of the 29 AS patients, 26 showed X-linked inheritance (mutations in \textit{COL4A5}), one showed autosomal recessive inheritance, and two showed DI. Among 32 mutations, 16 (50\%) were new amino acid substitutions of glycine. Indeed, glycine substitutions within the repetitive triplet sequence (Gly)-X-Y of the collagenous domain represent one of the most common type of pathogenic variant found in AS patients (Liu et al., 2017), as they are suspected to introduce kinks in the molecule, thus interfering with the proper folding of the collagen triple helix (Kashtan, 1993; Wang, Ding, Wang, & Bu, 2004). Overall, symptoms of female in XLAS exhibited more modest clinical manifestations than male in XLAS; patients with nonsense mutations, frameshift mutations, deletion mutations and splicing mutations presented relatively more severe symptoms than others. Female patients IID7 (p.(Pro1103Alafs*31)), IID9 (p.(Pro385Leufs*89)), and II26 (c.2395 + 2T>C) exhibited only moderate proteinuria, microscopic hematuria, and normal renal function. Male patients IID27 (c.2146 + 2T>A) and IID5 (deletion of exon37-46) presented relatively more severe symptoms, such as grosser hematuria or proteinuria and chronic kidney disease (CKD) and IID24 showed grosser hematuria, proteinuria and extra renal manifestations (Table 1). Patients IID6 (deletion of exon35-36) and IID25 (c.439-1G > A) exhibited the modest clinical symptoms, but considering their young age, further follow-up is necessary for their clinical symptoms.

IID3 with compound heterozygosity mutations (p.(Arg1517His) and p.(Arg1569Ter)) in \textit{COL4A5} inherited from her parents showed grosser hematuria, proteinuria, CKD and with extra renal manifestations. Although the two mutations have been reported as pathogenic, her mother with p.(Arg1569Ter) exhibited similar severe symptoms to the proband and her son (6 years) with p.(Arg1569Ter) presented hematuria and proteinuria; however, her father with p.(Arg1517His) did not presented any symptoms related to AS. This may be attributed to inter-familial phenotypic variability.

The patient IID28 with acute tubular injury carried two mutations (p. (Thr1474Met) from mother in \textit{COL4A4} and c.694-2A > C from father in \textit{COL4A4}) and showed autosomal recessive inheritance. Her father (69 years) exhibited hematuria, proteinuria and extra renal manifestations and was diagnosed with ADAS. Her mother (67 years) exhibited hematuria and proteinuria. This may indicate that splicing mutation c.694-2A > C probably played a dominant role in patient IID28.

**FIGURE 1** The identification of fragment deletions in \textit{COL4A5}. (a) The PCR quantification results of IID5. The comparison of quantification of exons 37–46 of \textit{COL4A5} between patient IID5 and controls. (b) The PCR quantification results of IID6. The comparison of quantification of exons 35–36 of \textit{COL4A5} between patient IID6 and controls. RQ, real-time quantitative PCR
In this study, using NGS (Ion Torrent PGM platform), we identified two AS families harboring mutations in two distinct collagen IV genes (digenic model) (Table 2). In patient IID27, we detected a de novo mutation in COL4A5 combined with a COL4A4 mutation. The female patient presents a severe phenotype, showing hematuria, proteinuria, and CKD. Her mother with c.1339 + 3A>T in COL4A5 and her father with a missense mutation c.4421C > T in COL4A4 had intermittent hematuria and proteinuria. In proband of family 29, in addition to a glycine substitution (p. (Gly1119Ala)) in COL4A3 in the heterozygous state, there was another heterozygous nonsense mutation c.5026C > T in COL4A4 genes. The two mutations were in cis configuration, inherited together on the same chromosome from her father. The proband exhibited hematuria, proteinuria, and renal insufficiency and her father showed microhematuria and proteinuria. This may be attributed to infrafamilial phenotypic variability. In this case, the inheritance pattern mimics an autosomal dominant form with a recurrence risk of 50%. However, the phenotype is more severe compared to an autosomal dominant pattern (Fallerini et al., 2017). This may indicate that AS patients with mutations in two different collagen genes show a more severe phenotype compared with those with a single mutation (Liu et al., 2017). According to the stoichiometry of the molecules of the triple helix, in double heterozygotes, about 75% of triple helix molecules are expected to be defective, which is > 50% in heterozygotes and < 100% in homozygotes or hemizygotes (Mencarelli et al., 2015). Therefore, in the case with mutations on the same autosomal chromosome (in cis) (family 30), a clinical re-evaluation on the basis of molecular data highlights the importance of considering a worse prognosis in comparison with an autosomal dominant mode of inheritance. (Artuso et al., 2012; Fallerini et al., 2014; Mencarelli et al., 2015; Pescucci et al., 2004). Conversely, a better prognosis should be considered in comparison with an autosomal recessive mode of inheritance, if the two mutations are independently inherited (in trans) (Fallerini et al., 2017; Wang et al., 2014; Zhang et al., 2012).

We analyzed the frequencies of the identified variant c. 2215C > G in COL4A5 from IID18 in ExAC (0.28%), 1,000 genome (0.34%) database and Chinese Gene Mutation Database (http://cngmd.virgilbio.com) (1.14% (more low in Han people (0.93%)). But more than 5% in the Japanese healthy population have this variant in COL4A5 (http://www.hgvd.genome.med.kyoto-u.ac.jp/cgi-bin/frequency_plot.cgi?chr=chrX&range=107846262-107846262-4&org_xml:id=1). The result may imply that there are some differences at some variants among different populations. The proband
was a 9-year-old female with first onset of gross hematuria at the age of 6. By the age of 7 years, she had already developed proteinuria, and laboratory investigation also confirmed high plasma creatinine. His mother showed intermittent microhematuria and proteinuria, and progressed to chronic kidney disease. Her grandmother and two sisters exhibited hematuria and proteinuria. This mutation was shown to co-segregate with the AS phenotype in the family. In addition, it has been reported that the c.2215C > G mutation may be one of pathogenic mutations underlying FSGS in Chinese (Zhang, Yang, & Hu, 2017). Therefore, we think that it was worth to discuss the clinical significance of this variant in Chinese.

In fact, we also found eight patients carrying a heterozygosity mutation in COL4A4 or COL4A3. These probands showed hematuria, low dose of proteinuria, and TBM, but was absence of a family history of ESRD (data not shown). Considering the modest clinical symptoms and their young age, further follow-up is necessary for their clinical symptoms (Mochizuki et al., 1994). This will be attributed to diagnosis these probands as ADAS or thin basement membrane nephropathy, which is also related to mutations in collagen IV genes (Stokman et al., 2016).

In conclusion, genetic testing is of great and increasing importance for diagnosing AS. The development of NGS has made possible the time- and cost-effective and accurate analysis of the three genes in a single step (Artuso et al., 2012; Morinieri et al., 2014). In this study, we think it is important to consider these transmission patterns in the clinical evaluation according to the results of genetic testing. The diversity of inheritance pattern in COL4A3, COL4A4, and COL4A5 can help us to explain the variable clinical expression of the disease. The identification of transmission patterns by NGS permit us to consider the recurrence risk in the families and make more reasonable genetic and prenatal counseling for AS.

ACKNOWLEDGMENTS

The authors wish to thank the subjects and families for participating in the study.

CONFLICT OF INTEREST

The authors report no relevant conflicts of interests related to the manuscript.

ORCID

Xiangdong Kong https://orcid.org/0000-0001-5685-8055

REFERENCES

Artuso, R., Fallerini, C., Dosa, L., Scionti, F., Clementi, M., Garosi, G., … Bruttini, M. (2012). Advances in Alport syndrome diagnosis using next-generation sequencing. European Journal of Human Genetics, 20(1), 50–57. https://doi.org/10.1038/ejhg.2011.164

Barker, D., Hostikka, S., Zhou, J., Chow, L., Olyphant, A., Gerken, S., … Tryggvason, K. (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science, 248(4960), 1224–1227. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2349482. https://doi.org/10.1126/science.2349482

Bekheirnia, M. R., Reed, B., Gregory, M. C., McFann, K., Shamshirsaz, A. A., Masoumi, A., & Schrier, R. W. (2010). Genotype-phenotype correlation in X-linked Alport syndrome. Journal of the American Society of Nephrology, 21(5), 876–883. https://doi.org/10.1681/ASN.2009070784

Boye, E., Flinter, F., Zhou, J., Tryggvason, K., Bobrow, M., & Harris, A. (1995). Detection of 12 novel mutations in the collagenous domain of the COL4A5 gene in Alport syndrome patients. Human Mutation, 5(3), 197–204. https://doi.org/10.1002/humu.1380050303

Cheong, H. I., Park, H. W., Ha, I. S., & Choi, Y. (2000). Mutational analysis of COL4A5 gene in Korean Alport syndrome. Pediatric Nephrology, 14(2), 117–121. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10684360. https://doi.org/10.1007/s004670050025

Fallerini, C., Baldassarri, M., Trevisson, E., Morbidoni, V., La Manna, A., Lazzarin, R., … Ariani, F. (2017). Alport syndrome: Impact of digenic inheritance in patients management. Clinical Genetics, 92(1), 34–44. https://doi.org/10.1111/cge.12919

Fallerini, C., Dosa, L., Tita, R., Del Prete, D., Feriozzi, S., Gai, G., … Ariani, F. (2014). Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clinical Genetics, 86(3), 252–257. https://doi.org/10.1111/cge.12258

Gross, O., Netzer, K. O., Lambrecht, R., Seibold, S., & Weber, M. (2002). Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: Impact on clinical counselling. Nephrology Dialysis Transplantation, 17(7), 1218–1227. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12105244. https://doi.org/10.1093/ndt/17.7.1218

Gubler, M. C. (2008). Inherited diseases of the glomerular basement membrane. Nature Clinical Practice Nephrology, 4(1), 24–37. https://doi.org/10.1038/ncpneph0671

Hanson, H., Storey, H., Pagan, J., & Flinter, F. (2011). The value of clinical criteria in identifying patients with X-linked Alport syndrome. Clinical Journal of the American Society of Nephrology, 6(1), 198–203. https://doi.org/10.2215/CJN.00200110

Hudson, B. G., Tryggvason, K., Sundaramoorthy, M., & Neilson, E. G. (2003). Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. New England Journal of Medicine, 348(25), 2543–2556. https://doi.org/10.1056/NEJMra022296

Jais, J. P., Knebelmann, B., Giatras, I., De Marchi, M., Rizzoni, G., Renieri, A., … Gubler, M. C. (2000). X-linked Alport syndrome: Natural history in 195 families and genotype-phenotype correlations in males. Journal of the American Society Nephrology, 11(4), 649–657. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10752524

Jais, J. P., Knebelmann, B., Giatras, I., De Marchi, M., Rizzoni, G., Renieri, A., … Gubler, M. C. (2003). X-linked Alport syndrome: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A "European Community Alport Syndrome Concerted Action" study. Journal of the American Society of Nephrology, 14(10), 2603–2610. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14514738. https://doi.org/10.1097/01ASN.0000090034.71205.74
